This can lead to significant financial burden to the patient as immunotherapy is expensive. its ligands and promotes immune responses including Nepicastat (free base) (SYN-117) antitumor immune response and antigen-specific T-cell responses to both foreign antigens as well as self-antigens. In 2013, the Food and Drug Administration granted fast track designation for nivolumab in NSCLC, RCC, and melanoma. Conclusion: The encouraging literature on nivolumab lends credibility to the promise of immune checkpoint blockade, not just in terms of its feasibility as an oncotherapeutic strategy but also as a key tool of the future in the therapeutic approaches against advanced cancers. = 135) administered IV at 3 mg/kg every 2 weeks or docetaxel (= 137) administered IV at 75 mg/m2 every 3 weeks. This study included patients regardless of their PD-L1 status. The trial excluded patients with autoimmune disease, symptomatic interstitial lung disease, or untreated brain metastasis. The first tumor assessment was conducted 9 weeks after randomization and continued every 6 weeks thereafter. The primary efficacy outcome Nepicastat (free base) (SYN-117) measure was OS. The trial demonstrated a statistically significant improvement in OS for patients randomized to nivolumab as compared with docetaxel at the prespecified interim analysis. Nivolumab in comparison with docetaxel demonstrated as follows: 41% reduction in risk of death (95% CI, 0.4, 0.8; = 0.00025) 1-year OS rate of 42.1% (95% CI, 33.7, 50.3) for nivolumab versus 23.7% (95% CI, 16.9C31.1) for docetaxel 1-year progression-free survival (PFS) rate of 20.8% (95% CI, 14.0C28.4) for nivolumab versus 6.4% (95% CI, 2.9C11.8) for docetaxel Median OS of 9.2 months (95% CI, 7.3C13.3) for nivolumab versus 6.0 months (95% CI, 5.1C7.3) for docetaxel Nivolumab demonstrated superior benefit across all endpoints independent of PD-L1 expression Nivolumab monotherapy demonstrated a favorable safety profile as compared to docetaxel in patients with previously treated advanced or metastatic SQ NSCLC. Safety profile of nivolumab was consistent with expectations based on prior data in terms of the type, frequency, and severity of reported events, and no new safety concerns with nivolumab monotherapy treatment were identified. Study CA209-063 (checkmate 063): Nivolumab in previously treated non-small cell lung cancer (squamous only) The phase II study CA209-06315 evaluated nivolumab monotherapy in patients with advanced, refractory, SQ NSCLC. In this study, 117 patients with stage IIIB or IV SQ NSCLC who had received 2 or more prior systemic therapies and had the Eastern Cooperative Oncology Group performance status of 0 or 1 were included in the study. Patients (N = 117) received nivolumab 3 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity. The major efficacy outcome measure was confirmed objective response rate (ORR) as measured by the Independent Review Committee (IRC) using the Response Evaluation Criteria in Solid Tumors (1.1). The first tumor assessment was conducted 8 weeks after the start of treatment and continued every 6 weeks thereafter. Based on IRC review and with a minimum follow-up of at least 10 months on all patients, results showed as follows: Confirmed ORR (IRC assessed): 17 of 117 (14.5%; 95% CI, 8.7C22.2) patients, of which all were PRs; 13 of 17 (76.5%) patients with a confirmed response had ongoing responses (duration ranging from 1.9+ to 11.5+ months) Median OS: 8.1 (95% CI, 6.1C10.9) months OS rate at 1 year: 39% (95% CI, 30C48) Responses were observed across PD-L1 expression levels and patient subgroups (age, race, gender, performance status, region, and number of prior therapies). Study CA209-057 (checkmate 057): Nivolumab versus docetaxel in previously treated nonsmall cell lung cancer (nonsquamous only) CA209-05716 was a phase III randomized (1:1), open-label study of 582 patients with metastatic non-SQ NSCLC who had experienced disease progression during or after one prior platinum doublet-based chemotherapy regimen. Appropriate prior targeted therapy in patients with known sensitizing epidermal growth factor receptor mutation or anaplastic lymphoma kinase translocation was allowed. Patients received nivolumab (= 292) administered IV at 3 mg/kg every 2 weeks or docetaxel (= 290) administered IV at 75 mg/m2 every 3 weeks. The first tumor assessments were conducted 9 weeks after randomization and continued every 6 weeks thereafter. The major efficacy outcome measure was OS. In addition, prespecified analyses were conducted in subgroups defined by PD-L1 expression. Nivolumab demonstrated a statistically significant improvement in OS compared with docetaxel at the prespecified interim analysis. Nivolumab in comparison with docetaxel demonstrated: 28% lower risk of death (hazard ratio, 0.72; 95% CI, 0.60C0.88; 0.001) median OS of 12.2 months (95% CI, 9.7C15.1).This study included patients regardless of their PD-L1 status. A total of 821 patients were randomized to receive either nivolumab 3 mg/kg (= 410) administered IV over 60 min every 2 weeks or everolimus (= 411) 10 mg daily, administered orally. the Food and Drug Administration granted fast track designation for nivolumab in NSCLC, RCC, and melanoma. Conclusion: The encouraging literature on nivolumab lends credibility to the promise of immune checkpoint blockade, not just in terms of its feasibility as an oncotherapeutic strategy but also as a key tool of the future in the therapeutic approaches against advanced cancers. = 135) administered IV at 3 mg/kg every 2 weeks or docetaxel (= 137) administered IV at 75 mg/m2 every 3 weeks. This study included patients regardless of their PD-L1 status. The trial excluded patients with autoimmune disease, symptomatic interstitial lung disease, or untreated brain metastasis. The first tumor assessment was conducted 9 weeks after randomization and continued every 6 weeks thereafter. The primary efficacy outcome measure was OS. The trial demonstrated a statistically significant improvement in OS for Nepicastat (free base) (SYN-117) patients randomized to nivolumab as compared with docetaxel at the prespecified interim analysis. Nivolumab in comparison with docetaxel demonstrated as follows: 41% reduction in risk of death (95% CI, 0.4, 0.8; = 0.00025) 1-year OS rate of 42.1% (95% CI, 33.7, 50.3) for nivolumab versus 23.7% (95% CI, 16.9C31.1) for docetaxel 1-year progression-free survival (PFS) rate of 20.8% (95% CI, 14.0C28.4) for nivolumab versus 6.4% (95% CI, 2.9C11.8) for docetaxel Median OS of 9.2 months (95% CI, 7.3C13.3) for nivolumab versus 6.0 months (95% CI, 5.1C7.3) for docetaxel Nivolumab demonstrated superior benefit across all endpoints independent of PD-L1 expression Nivolumab monotherapy demonstrated a favorable safety profile as compared to docetaxel in patients with previously treated advanced or metastatic SQ NSCLC. Safety profile of nivolumab was consistent with expectations based on prior data in terms of the type, frequency, and severity of reported events, and no new safety concerns with nivolumab monotherapy treatment were identified. Study CA209-063 (checkmate 063): Nivolumab in previously treated non-small cell lung cancer (squamous only) The phase II study CA209-06315 evaluated nivolumab monotherapy in patients with advanced, refractory, SQ NSCLC. In this study, 117 patients with stage IIIB or IV SQ NSCLC who had received 2 or more prior systemic therapies and had the Eastern Cooperative Oncology Group performance status of 0 or 1 were included in the study. Patients (N = 117) received nivolumab 3 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity. The major efficacy outcome measure was confirmed objective response rate (ORR) as measured by the Independent Review Committee (IRC) using the Response Evaluation Criteria in Solid Tumors (1.1). The first tumor assessment was conducted 8 weeks after the start of treatment and continued every 6 weeks thereafter. Based on IRC review and with a minimum follow-up of at least 10 months on all patients, results showed as follows: Confirmed ORR (IRC assessed): 17 of 117 (14.5%; 95% CI, 8.7C22.2) patients, of which all were PRs; 13 of 17 (76.5%) patients with a confirmed response had ongoing responses (duration ranging from 1.9+ to 11.5+ months) Median OS: 8.1 (95% CI, 6.1C10.9) months OS rate at 1 year: 39% (95% CI, 30C48) Responses were observed across PD-L1 expression levels and patient subgroups (age, race, gender, performance status, region, and number of prior therapies). Study CA209-057 (checkmate 057): Nivolumab versus docetaxel in previously treated nonsmall cell lung malignancy (nonsquamous only) CA209-05716 was a phase III randomized (1:1), open-label study of 582 individuals Nepicastat (free base) (SYN-117) with metastatic non-SQ NSCLC who experienced experienced disease progression during or after one previous platinum doublet-based chemotherapy routine. Appropriate prior targeted therapy in individuals with known sensitizing epidermal growth element receptor mutation AMPK or anaplastic lymphoma kinase translocation was allowed. Individuals received nivolumab (= 292) given IV at 3 mg/kg every 2 weeks or docetaxel (= 290) given IV at 75 mg/m2 every 3 weeks. The 1st tumor assessments were conducted 9.